| Frédéric Guerard |
Presently, Frédéric Guerard holds the position of President, Chief Executive Officer & Director at Graybug Vision, Inc. Dr. Guerard is also on the board of LENZ Therapeutics, Inc.
He previously occupied the position of Head-Ophthalmology at Novartis AG and Head-Global Franchise Pharmaceuticals at Alcon Vision LLC.
He received a graduate degree and a doctorate from Université de Rouen Normandie and a graduate degree from École des Hautes Études Commerciales de Paris. |
| Robert S. Breuil |
Presently, Robert S. Breuil holds the position of Chief Financial Officer of Graybug Vision, Inc.
In his past career Mr. Breuil was Chief Financial Officer for Codexis, Inc., Chief Financial Officer of Corium International, Inc., Chief Financial Officer & VP-Corporate Development at Aerogen, Inc., Director-Corporate Planning, Analysis & Controller at ALZA Corp. and Controller of ALZA Pharmaceuticals.
He received an undergraduate degree from United States Naval Academy and an MBA from Stanford Graduate School of Business. |
| Christy L. Shaffer |
Christy L. Shaffer is a businessperson who has been the head of 8 different companies and presently occupies the position of Chairman at Graybug Vision, Inc., Chairman of Kinodyn, Inc. and General Partner of Hatteras Venture Partners. She is also Managing Director at Hatteras Discovery and on the board of 10 other companies.
She previously occupied the position of Executive Chairman of G1 Therapeutics, Inc., Chairman of Trefoil Therapeutics, Inc., Principal at The North Carolina Biotechnology Center, Chairman at Cystic Fibrosis Foundation Therapeutics, Inc., President, Chief Executive Officer & Director at Inspire Pharmaceuticals, Inc., Associate Director-Pulmonary & Critical Care at Burroughs Wellcome, Associate Director at Pulmonary Critical Care Management, Inc. and Director at North Carolina School of Science & Mathematics Foundation.
Christy L. Shaffer received a doctorate from The University of Tennessee Health Science Center. |
| Parisa Zamiri |
Parisa Zamiri holds the position of Chief Medical Officer for Graybug Vision, Inc.
In the past Dr. Zamiri held the position of Director-Pre-Clinical Sciences at Arsenal Medical, Inc. and VP & Global Head-Clinical Development at Novartis AG.
She received a graduate degree from King's College London and a doctorate from University College London. |
| Bettina Maunz |
Bettina Maunz holds the position of Chief People Officer & Head-Communications at Graybug Vision, Inc.
In her past career Ms. Maunz occupied the position of VP & Global Head-Communications at Alcon Pharmaceuticals Cham, President at Alcon Foundation, Inc., Vice President & Global Head-Communications at Ciba Vision Corp. and Head-Communications at Novartis Pharmaceuticals Corp.
She received an undergraduate degree from Mannheim Business School gGmbH. |
| Christina Maria Ackermann |
Currently, Christina Maria Ackermann is Head-Commercial Operations at Bausch Health Cos., Inc. and Co-Managing Director at Dr. Robert Winzer Pharma GmbH, Secretary & Director at Synergetics USA, Inc. and Executive Vice President & General Counsel of Bausch + Lomb Corp. (which are all subsidiaries of Bausch Health Cos., Inc.). Ms. Ackermann is also on the board of Graybug Vision, Inc. and Oculis Holding AG.
In her past career she occupied the position of Associate General Counsel at DuPont Pharmaceuticals Co., Associate General Counsel at Bristol-Myers Squibb Pharma Co., Head-Legal General Medicine at Novartis Pharma AG, Senior Vice President & General Counsel at Alcon Laboratories, Inc. and General Counsel & Global Head-Legal at Sandoz International GmbH.
Ms. Ackermann received a graduate degree from Queen's University, an undergraduate degree from York University and a graduate degree from King's College London. |
| Julia Marie Eastland |
Presently, Julia Marie Eastland holds the position of President, Chief Executive Officer & Director at Harpoon Therapeutics, Inc. She is also on the board of Dynavax Technologies Corp. and Graybug Vision, Inc.
She previously occupied the position of Chief Financial Officer & VP-Operations at Viral Logic Systems Technology Corp., Chief Operating & Financial Officer for ReCode Therapeutics, Inc., Finance Manager at Amgen, Inc., Director-Finance & Planning at Encore Media Group, Manager-Business & International Finance at Science Magazine, Finance Director at Biovail Corp., CFO, Secretary & VP-Corporate Development at Cascadian Therapeutics LLC, Chief Financial & Business Officer at Rainier Therapeutics, Inc., Vice President-Strategic Planning at Dendreon Corp. and Financial Manager at Discovery Channel.
Ms. Eastland received an undergraduate degree from Colorado State University and an MBA from the University of Edinburgh Business School. |
| Eric Hands Claude Bjerkholt |
Founder of Kenady LLC, Eric Hands Claude Bjerkholt is Chief Financial Officer of Chinook Therapeutics, Inc. He is also on the board of 5 other companies.
Mr. Bjerkholt previously was President, Chief Executive & Financial Officer at Kenady LLC, President, Chief Executive & Financial Officer at LifeSpring Home Nutrition, Chief Financial Officer & Senior Vice President for IntraBiotics Pharmaceuticals, Inc., CFO, Secretary & EVP-Corporate Development at Sunesis Pharmaceuticals, Inc., Chief Financial Officer at Aimmune Therapeutics, Inc. and Vice President at J.P. Morgan & Co., Inc. (Delaware).
Mr. Bjerkholt received an undergraduate degree from the University of Oslo and an MBA from Harvard Business School. |
| Dirk Sauer |
Dirk Sauer is on the board of Iconic Therapeutics, Inc. and Graybug Vision, Inc.
In his past career Dr. Sauer was Head-Ophthalmology & Global Development Unit at Novartis International AG.
Dr. Sauer received an undergraduate degree from the University of Münster and a doctorate from Philipps University of Marburg. |
